Background: Heart failure with reduced ejection fraction (HFrEF) people are exposed to
increased risk of death that can be predicted by several factors, one of which is increased …

Increased vascular stiffness is known to be an independent predictor of mortality in patients
with heart failure with reduced ejection fraction (HFrEF). The effects of sacubitril–valsartan …

Background: Increased aortic stiffness is known to be an independent predictor of mortality
in patients with heart failure with reduced ejection fraction (HFrEF). The effects of sacubitril …

Background: The multiple beneficial effects of sacubitril/valsartan in the treatment of heart
failure with reduced ejection fraction are vastly known, but still no or few mentions have …

Aims It has already been demonstrated the efficacy of sacubitril/valsartan in the treatment of
heart failure with reduced ejection fraction, but many of its properties are still unknown …

Background: Sacubitril/valsartan effectively treats HFrEF complications by combining
vasodilatory and RAAS inhibitory actions. Its effects on myocardial and hepatic stiffness are …

Heart failure (HF) is associated to endothelial dysfunction that promotes the increase of
arterial stiffness thus augmenting myocardial damage. Sacubitril/Valsartan is used in the …

Importance Compared with enalapril, sacubitril-valsartan reduces cardiovascular mortality
and heart failure hospitalization in patients with heart failure and reduced ejection fraction …

Background Heart failure (HF) is associated to endothelial dysfunction, a pathological
condition characterized by imbalance between the production of vasoconstrictor and …

Aim. To study the effects of sacubitril/valsartan on left ventricular-arterial coupling (LVAC)
and arterial stiffness in HFrEF patients. Material and methods. Arterial stiffness by …